RSS | Login | Register

IXIARO

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare IXIARO to:

Generic Name for IXIARO

Japanese encephalitis virus vaccine; inactivated; aluminum hydroxide adsorbed; susp for IM inj; contains formaldehyde, protamine sulfate; preservative-free.

Legal Classification:

Pharmacological Class for IXIARO

Japanese encephalitis vaccine.

Manufacturer of IXIARO

Novartis Pharmaceuticals Corp

Indications for IXIARO

Japanese encephalitis immunization.

Adult dose for IXIARO

≥17yrs: Two doses given 28 days apart. Each dose is 0.5mL IM into deltoid muscle; complete series at least 1 week prior to potential exposure.

Children's dosing for IXIARO

<17yrs: not recommended.

Contraindications for IXIARO

Severe allergic reaction (eg, anaphylaxis) after a previous dose.

Warnings/Precautions for IXIARO

Immunodeficiency. Bleeding disorders. Acute febrile illness. Allergy to protamine sulfate. Have epinephrine inj (1:1000) available. Pregnancy (Cat.B). Nursing mothers.

Interactions for IXIARO

Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.

Adverse Reactions for IXIARO

Local reactions (eg, pain, tenderness), headache, myalgia, fatigue, flu-like illness, GI upset, pyrexia.

How is IXIARO supplied?

Single-dose syringe (0.5mL)—1

Related Disease:

Immunization

FDA accepts sBLA for Menactra for immunization of infants and toddlers

August 26, 2010

Sanofi Pasteur announced that the FDA has accepted for review a supplemental Biologics License Application (sBLA) for the use of Menactra (Meningococcal [Groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

FluLaval and Fluarix vaccines for 2010-2011 influenza season

July 30, 2010

GlaxoSmithKline announced that it has begun shipping the 2010-2011 formulation of FluLaval (trivalent, inactivated, "split virus" influenza vaccine [Types A and B]) and anticipates distributing Fluarix (trivalent, inactivated, "split virus" influenza vaccine [Types A and B]) in the next several weeks.

FluMist available for 2010-2011 influenza season

July 26, 2010

MedImmune announced that it has begun shipping FluMist (intranasal, live, attenuated influenza vaccine) to vaccine distributors who service healthcare providers.